Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553271 | 0.95 | TYR (0.47) | TYRNPC1RAB9ASLC5A1SLC5A2 | |
| SCHEMBL29941871 | 0.83 | TYR (0.57) | TYRNPC1RAB9ASLC5A1 | |
| SCHEMBL29392767 | 0.81 | TYR (0.54) | TYRNPC1RAB9ASLC5A1 | |
| SCHEMBL28049269 | 0.81 | TYR (0.56) | TYRNPC1RAB9ASLC5A1 | |
| SCHEMBL31509502 | 0.80 | TYR (0.48) | TYRNPC1RAB9ASLC5A1SLC5A2 | |
| SCHEMBL30047083 | 0.80 | TYR (0.50) | TYRNPC1RAB9ASLC5A1SLC5A2 | |
| SCHEMBL29392493 | 0.79 | TYR (0.52) | TYRNPC1RAB9ASLC5A1 | |
| SCHEMBL28755274 | 0.79 | TYR (0.51) | TYRNPC1RAB9ASLC5A1 | |
| Vandateroside I SCHEMBL15022617 | 0.79 | TYR (0.60) | TYRNPC1RAB9ASLC5A1SLC5A2 | |
| Vandateroside I SCHEMBL15033271 | 0.79 | TYR (0.60) | TYRNPC1RAB9ASLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556080-A1 | COSMETIC COMPOSITION | Guerlain (FR) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125057-A1 | COSMETIC COMPOSITION | GUERLAIN (FR) | 2011-10-13 | — | — | WO | disclosed |